Sebastian Gensior

Executive Summary OpenAI's expansion into healthcare represents a significant inflection point in the artificial intelligence industry, driven by measurable performance improvements, strategic partnerships with major pharmaceutical companies, and demonstrable technical capabilities that extend far beyond conversational AI. Through the third quarter of 2025, the company has established itself

Fund Launch and Structure Clinique La Prairie, the Swiss medical spa founded in 1931, launched its Longevity Fund in October 2024 with a target of €300 million across three closing phases. The announcement came during a period of recovery for longevity investing, which saw funding increase to $8.5 billion

Executive Summary The integration of artificial intelligence into biotechnology has reached a critical inflection point in 2025. This comprehensive analysis examines the current state of AI deployment across drug discovery, protein structure prediction, and biomedical research, presenting objective performance metrics and market dynamics. Key findings indicate significant progress in specific

Executive Summary: The $7.8 billion question The generative AI revolution in biotech synthetic data generation stands at a critical inflection point in 2025, with $7.8 billion invested in H1 2025 alone and market projections ranging from $1.5 billion to $20.3 billion by 2030. This comprehensive analysis

The promise of cellular reprogramming through Yamanaka factors represents one of the most profound scientific contradictions in modern medicine: a Nobel Prize-winning technology with 109% lifespan extension in aged mice and $6+ billion in investment, yet plagued by <1% efficiency rates, severe cancer risks, and zero approved human therapies

Weekly Term Sheet: Pharma & Biotech Deals (August 25–28, 2025) Key Deal Highlights Deal Type Companies Value Key Asset/Focus Acquisition AbbVie acquires Gilgamesh Up to $1.2B Bretisilocin (psychedelic therapy) Royalty Purchase Royalty Pharma buys BeOne's Imdelltra royalty $950M Amgen's lung cancer BiTE R&

Introduction: A Wave of Biosimilar Challenges and the "Patent Cliff" The biopharmaceutical industry is witnessing a surge of patent infringement battles over biosimilars in 2025. A major reason is the "patent cliff" -- a wave of blockbuster biologic drugs losing patent protection around this time. As

Investor Syndicate and Stakeholders in the $300 Million Round The new biotech (not yet officially named) is backed by a $300 million financing commitment led by Bain Capital, with other key stakeholders and co-investors involved. Beyond Bain's Life Sciences and Private Equity funds, the Canada Pension Plan Investment

Origin Story: From Niche Pioneer to Public Trust DRI Healthcare's roots go back to 1989, when it began as one of the first investment groups dedicated to pharmaceutical royalty monetization. Originally known as Drug Royalty Corporation, the firm spent the 1990s and 2000s quietly building expertise in buying

The biotech investment ecosystem in late August 2025 presents a complex landscape of cautious recovery, selective capital deployment, and strategic adaptation to persistent market challenges. With nearly 40% of biotechs operating with less than 12 months of cash runway and the XBI index showing mixed performance, the sector is navigating